Idorsia (IDIA) Aperçu de l'action
Idorsia Ltd, société biopharmaceutique, se consacre à la découverte, au développement et à la commercialisation de médicaments destinés à répondre à des besoins médicaux non satisfaits en Suisse, aux États-Unis, au Japon, en Europe et au Canada. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 4/6 |
| Performances passées | 0/6 |
| Santé financière | 0/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
IDIA Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Idorsia Ltd Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | CHF 4.76 |
| Plus haut sur 52 semaines | CHF 7.56 |
| Plus bas sur 52 semaines | CHF 2.80 |
| Bêta | 1.64 |
| Variation sur 1 mois | -19.56% |
| Variation sur 3 mois | 2.32% |
| Variation sur 1 an | 13.42% |
| Variation sur 3 ans | 30.93% |
| Variation sur 5 ans | -78.49% |
| Évolution depuis l'introduction en bourse | -65.14% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Sep 14
IDIA: Sleep Franchise Execution Will Shape Future Equity Upside Path
The analyst price target for Idorsia has shifted from CHF 5.50 to CHF 6.00. Analysts attribute the change to updated long term expectations for daridorexant, as well as refreshed assumptions for revenue growth, profit margins and future P/E multiples.Mise à jour du récit • Aug 15
IDIA: Funding Headroom And Sleep Franchise Outlook Will Shape Future Equity Path
Idorsia's analyst price target has increased to CHF 5.50 from CHF 5.00. Analysts attribute the change to updated assumptions for revenue growth, profit margins, discount rate and future P/E.
Mise à jour du récit • Jul 31
IDIA: Future Pediatric Sleep And Vaccine Pipeline May Not Justify Current Optimism
Analysts have raised their price target on Idorsia by CHF 0.50 to CHF 4.50, citing updated assumptions on fair value, revenue growth, profit margin and future P/E expectations. What’s in the News for Idorsia Idorsia reported QUVIVIQ sales of CHF 91 million for the first half of 2026, with the company reaffirming its full year 2026 guidance and highlighting four key drivers of future growth, including QUVIVIQ market expansion and TRYVIO/JERAYGO commercialization.Recent updates
Mise à jour du récit • Sep 14
IDIA: Sleep Franchise Execution Will Shape Future Equity Upside Path
The analyst price target for Idorsia has shifted from CHF 5.50 to CHF 6.00. Analysts attribute the change to updated long term expectations for daridorexant, as well as refreshed assumptions for revenue growth, profit margins and future P/E multiples.Mise à jour du récit • Aug 15
IDIA: Funding Headroom And Sleep Franchise Outlook Will Shape Future Equity Path
Idorsia's analyst price target has increased to CHF 5.50 from CHF 5.00. Analysts attribute the change to updated assumptions for revenue growth, profit margins, discount rate and future P/E.Mise à jour du récit • Jul 31
IDIA: Future Pediatric Sleep And Vaccine Pipeline May Not Justify Current Optimism
Analysts have raised their price target on Idorsia by CHF 0.50 to CHF 4.50, citing updated assumptions on fair value, revenue growth, profit margin and future P/E expectations. What’s in the News for Idorsia Idorsia reported QUVIVIQ sales of CHF 91 million for the first half of 2026, with the company reaffirming its full year 2026 guidance and highlighting four key drivers of future growth, including QUVIVIQ market expansion and TRYVIO/JERAYGO commercialization.Mise à jour du récit • Jul 10
IDIA: Future CEO Transition And Debt Refinancing Will Test Equity Downside
Analysts recently lifted their price target on Idorsia to CHF 4.50 from CHF 4.00, citing updated assumptions for revenue growth, profit margins, discount rates and future P/E levels in their valuation work. What’s in the News for Idorsia Idorsia appointed Roland Wandeler, PhD, as Chief Executive Officer effective October 1, 2026.
Mise à jour du récit • Jun 26
IDIA: Pharmakon Debt Will Likely Constrain Long-Term Upside Potential
Analysts recently lifted their price target on Idorsia stock from CHF 4.00 to CHF 4.50, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What’s in the News for Idorsia Idorsia confirmed the closing of a senior secured term loan of up to CHF 250 million with funds managed by Pharmakon Advisors.Mise à jour du récit • Jun 05
IDIA: Pediatric Sleep And Vaccine Pipeline Will Support Future Upside Despite Higher Costs
Analysts have lowered their price target on Idorsia to CHF 5, down from CHF 6. They cite reduced forward visibility and higher operating expenses as the main reasons for this adjustment.Mise à jour du récit • May 04
IDIA: Pediatric And Fabry Pipelines Will Support Future Upside Despite Higher Costs
Analysts have reduced their 12 month price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as the main reasons for the change. Analyst Commentary Bullish Takeaways Bullish analysts maintain a positive stance on the shares even after the price target move to CHF 5, which signals that they still see potential upside from current levels.Mise à jour du récit • Apr 18
IDIA: Fabry And Pediatric Programs Will Drive Future Upside Despite Higher Costs
Analysts have trimmed their price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as key reasons for the adjustment. Analyst Commentary Recent commentary points to a mixed view on Idorsia, with the reduced price target reflecting both confidence in parts of the story and concern about execution risks and spending.Mise à jour du récit • Apr 04
IDIA: Fabry Pipeline Progress Will Continue To Drive Future Upside
Analysts have trimmed their 12 month price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as the key reasons for the reset. Analyst Commentary Bullish Takeaways Bullish analysts are still assigning upside potential to Idorsia shares even after the target reset to CHF 5, which signals that they see value at current levels despite near term headwinds.Mise à jour du récit • Mar 20
IDIA: Fabry And Resistant Hypertension Progress Will Continue To Drive Future Upside
Analysts have trimmed their price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as key reasons for the adjustment. Analyst Commentary Recent research points to a mixed view on Idorsia, with the reduced price target reflecting both confidence in parts of the story and concern around execution and cost control.Mise à jour du récit • Mar 05
IDIA: Fabry And Resistant Hypertension Progress Will Likely Drive Future Upside
Analysts have revised their CHF price targets for Idorsia to reflect updated assumptions for discount rates, revenue growth, profit margins and future P/E. They are now presenting a more balanced view of the company’s risk and earnings potential.Mise à jour du récit • Feb 19
IDIA: Fabry And Hypertension Pipeline Advances Will Likely Drive Future Upside
Analysts have adjusted their CHF price target on Idorsia based on updated assumptions around discount rates, revenue, profit margins, and a higher expected future P/E multiple, resulting in a revised valuation framework in CHF terms. What's in the News Idorsia outlined an FDA-agreed Phase 3 registration program for lucerastat in Fabry disease, centered on kidney pathology and including a pivotal biopsy study plus a second trial comparing oral therapy with current standard-of-care to support a potential market authorization pathway (Key Developments).Mise à jour du récit • Feb 04
IDIA: Hypertension And Insomnia Pipeline Progress Will Likely Drive Future Upside
Analysts have trimmed their price target on Idorsia to reflect a slightly lower profit margin outlook and a higher assumed future P/E of 31.60x, while keeping their fair value estimate broadly unchanged. What's in the News Idorsia signed an exclusive license and supply agreement with EMS S.A. to bring QUVIVIQ (daridorexant) to patients across Latin America.Mise à jour du récit • Jan 21
IDIA: Hypertension And Insomnia Franchise Will Likely Drive Future Upside
Analysts have adjusted their price target on Idorsia slightly lower to reflect updated assumptions around fair value, a modestly higher discount rate, more conservative revenue growth expectations, a similar profit margin outlook, and a higher future P/E multiple. What's in the News Publication of Phase 3 MODIFY and open label extension data for lucerastat in Fabry disease, with results in Nature Communications highlighting sustained biomarker reductions and signals on renal and cardiac function in a small patient population.Mise à jour du récit • Jan 07
IDIA: Hypertension And Insomnia Assets Will Likely Drive Future Upside
Analysts have kept their price target for Idorsia broadly unchanged. They cite only small tweaks to inputs such as a slightly higher discount rate, steady revenue growth and profit margin assumptions, and a marginally adjusted future P/E multiple as the basis for their updated view.Article d’analyse • Dec 22
Idorsia Ltd (VTX:IDIA) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Idorsia Ltd ( VTX:IDIA ) shares have had a really impressive month, gaining 28% after a shaky period beforehand. The...Mise à jour du récit • Dec 17
IDIA: Hypertension And Insomnia Portfolio Will Likely Deliver Upside From Current Levels
Analysts have raised their price target for Idorsia significantly, citing a higher fair value estimate of 5.0 dollars, stronger anticipated revenue growth, and an expectation of a materially higher future price to earnings multiple, partially offset by a slightly lower discount rate. What's in the News Idorsia reaffirmed 2025 guidance, targeting around CHF 130 million in QUVIVIQ net sales and a US-GAAP operating loss of about CHF 55 million for the global business, supported by approximately CHF 165 million EBIT from partnered activities (corporate guidance).Mise à jour du récit • Dec 03
IDIA: Hypertension And Insomnia Portfolio Will Likely Fail To Justify Current Price
Analysts have modestly raised their price target on Idorsia, citing a slightly lower perceived risk profile and a marginally stronger long term profit outlook that supports a small increase in fair value, now estimated at approximately 2.00. What's in the News Reaffirmed 2025 guidance, projecting QUVIVIQ net sales around CHF 130 million, partnered business US-GAAP EBIT of about CHF 165 million, and a global US-GAAP operating loss of roughly CHF 55 million, mainly driven by the amended Viatris deal (corporate guidance).Mise à jour du récit • Nov 19
IDIA: Limited Near-Term Upside Expected Despite Recent Price Reassessment
Narrative Update on Idorsia Analysts have raised their price target for Idorsia, doubling it from CHF 1 to CHF 2. This change is attributed to improved outlooks in key financial metrics, including a slightly lower discount rate and stable revenue growth projections.Article d’analyse • Nov 07
Little Excitement Around Idorsia Ltd's (VTX:IDIA) Revenues As Shares Take 29% Pounding
The Idorsia Ltd ( VTX:IDIA ) share price has softened a substantial 29% over the previous 30 days, handing back much of...Mise à jour du récit • Nov 03
IDIA: Near-Term Risks Will Likely Limit Upside Despite Price Target Lift
Analysts have increased their price target for Idorsia by CHF 1.00 to CHF 2.00. They cite improved revenue growth projections and a more favorable future price-to-earnings outlook, despite a slightly higher discount rate and modestly lower profit margin expectations.Mise à jour du récit • Sep 23
Global Expansion And FDA Review Will Moderate Overvaluation
Despite a decline in revenue growth forecasts, the significant rise in Idorsia’s future P/E multiple underpins the sharp increase in its consensus analyst price target from CHF2.00 to CHF4.00. What's in the News Simcere Pharmaceuticals launched QUVIVIQ (daridorexant), Idorsia's dual orexin receptor antagonist for insomnia, in China, with approval highlighting its differentiated clinical profile and lack of psychotropic labeling.Article d’analyse • Sep 14
Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry
Idorsia Ltd ( VTX:IDIA ) shares have continued their recent momentum with a 38% gain in the last month alone. The...Nouveau récit • Sep 08
Global Expansion And FDA Review Will Moderate Overvaluation
Key Takeaways Market optimism for rapid revenue growth may be premature, with unvalidated access, uncertain drug uptake, and regulatory outcomes adding risk to earnings expectations. Longer-term valuation appears inflated by pipeline commercialization hopes, while rising costs and increasing pricing scrutiny threaten future margins and profitability.Article d’analyse • Aug 24
New Forecasts: Here's What Analysts Think The Future Holds For Idorsia Ltd (VTX:IDIA)
Shareholders in Idorsia Ltd ( VTX:IDIA ) may be thrilled to learn that the covering analyst has just delivered a major...Article d’analyse • Jul 19
There's Reason For Concern Over Idorsia Ltd's (VTX:IDIA) Massive 46% Price Jump
Despite an already strong run, Idorsia Ltd ( VTX:IDIA ) shares have been powering on, with a gain of 46% in the last...Article d’analyse • Dec 19
Improved Revenues Required Before Idorsia Ltd (VTX:IDIA) Stock's 71% Jump Looks Justified
Idorsia Ltd ( VTX:IDIA ) shareholders are no doubt pleased to see that the share price has bounced 71% in the last...Article d’analyse • Nov 06
One Idorsia Ltd (VTX:IDIA) Analyst Has Been Cutting Their Forecasts
The latest analyst coverage could presage a bad day for Idorsia Ltd ( VTX:IDIA ), with the covering analyst making...Article d’analyse • Nov 04
Market Cool On Idorsia Ltd's (VTX:IDIA) Revenues Pushing Shares 33% Lower
To the annoyance of some shareholders, Idorsia Ltd ( VTX:IDIA ) shares are down a considerable 33% in the last month...Rendement pour les actionnaires
| IDIA | CH Biotechs | CH Marché | |
|---|---|---|---|
| 7D | -7.2% | -1.0% | -2.5% |
| 1Y | 13.4% | 17.0% | 11.8% |
Rendement vs Industrie: IDIA a sous-performé le secteur Swiss Biotechs qui a rapporté 17 % au cours de l'année écoulée.
Rendement vs marché: IDIA a dépassé le marché Swiss qui a rapporté 11.8 % au cours de l'année écoulée.
Volatilité des prix
| IDIA volatility | |
|---|---|
| IDIA Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.0% |
Cours de l'action stable: Le cours de l'action de IDIA a été volatil au cours des 3 derniers mois par rapport au marché Swiss.
Volatilité au fil du temps: La volatilité hebdomadaire de IDIA ( 11% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de Swiss.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2017 | 456 | Jean-Paul Clozel | www.idorsia.com |
Idorsia Ltd, société biopharmaceutique, se consacre à la découverte, au développement et à la commercialisation de médicaments destinés à répondre à des besoins médicaux non satisfaits en Suisse, aux États-Unis, au Japon, en Europe et au Canada. La société dispose d'un pipeline de développement clinique pour divers domaines thérapeutiques, tels que le SNC, les maladies cardiovasculaires, les troubles immunologiques et les maladies orphelines. Elle propose QUVIVIQ (daridorexant) pour le traitement de l'insomnie.
Idorsia Ltd Résumé des fondamentaux
| IDIA statistiques fondamentales | |
|---|---|
| Capitalisation boursière | CHF 1.25b |
| Bénéfices(TTM) | -CHF 316.18m |
| Recettes(TTM) | CHF 199.71m |
6.3x
Ratio P/S-4.0x
Ratio P/ELe site IDIA est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| IDIA compte de résultat (TTM) | |
|---|---|
| Recettes | CHF 199.71m |
| Coût des recettes | CHF 136.73m |
| Marge brute | CHF 62.99m |
| Autres dépenses | CHF 379.17m |
| Les revenus | -CHF 316.18m |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
Oct 29, 2026
| Résultat par action (EPS) | -1.20 |
| Marge brute | 31.54% |
| Marge bénéficiaire nette | -158.32% |
| Ratio dettes/capitaux propres | -101.4% |
Quelles ont été les performances à long terme de IDIA?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/15 23:11 |
| Cours de l'action en fin de journée | 2026/09/15 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Idorsia Ltd est couverte par 10 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Rosie Turner | Barclays |
| Alistair Campbell | Berenberg |
| Sachin Jain | BofA Global Research |